Chris Molloy on mRNA cancer vaccine reaching Phase 3 milestone, Scancell MHRA authorisation, microbiome-based medicinal products, MHRA voucher scheme for SMEs, Scotland and data driver projects
Claire Smith, who sits on BIA’s Intellectual Property Advisory Committee (IPAC) committee, and James Johnston explain what the US BIOSECURE Act means for UK biotech companies
Opening for participation on September 2nd 2026, PIR International’s 2027 EU/UK Biotech & Life Sciences Board Remuneration & Diversity Study will provide a comprehensive, data-driven view of board remuneration, composition and diversity across the European and UK life sciences sector.
Chris Molloy on Mike Hoare, the RedX-Skye deal, Stablepharma’s fridge-free vaccine, MHRA quarterly numbers, ministerial responsibilities for UK life sciences and human biology-based models
The Milner Therapeutics Institute (MTI) is proud to be part of a new £20 million Medical Research Council (MRC) investment that will establish a UK Pre-clinical Translational Models Hub.
MORF-Bio has secured an Innovate UK Investor Partnerships Award, unlocking a new investment round led by Deeptech Seed Fund and matched by Helix Research and Enterprise.
Chris Molloy on new pension scale-up fund news, member news from Touchlight, the major GSK investment in Cambridge, a valuable collaboration for Relation and BIA's parliamentary engagement